JNJ vs. RDY: Johnson & Johnson vs. Dr. Reddy's Laboratories Stock Comparison

Company Profile

Johnson & Johnson (JNJ) and Dr. Reddy's Laboratories (RDY) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Johnson & Johnson (JNJ) trades as ordinary local shares, while Dr. Reddy's Laboratories (RDY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Johnson & Johnson (JNJ) at 20.02% and Dr. Reddy's Laboratories (RDY) at 7.34% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both Johnson & Johnson (JNJ) at 16.20% and Dr. Reddy's Laboratories (RDY) at 8.49% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Johnson & Johnson (JNJ) at 25.74% operates in the top operating margin quartile, ahead of Dr. Reddy's Laboratories (RDY) at 14.73%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Johnson & Johnson (JNJ) at 6.05% and Dr. Reddy's Laboratories (RDY) at 3.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Johnson & Johnson (JNJ) at 90.50% sits in the top EPS growth quartile, while Dr. Reddy's Laboratories (RDY) at -24.14% is closer to the peer norm — faster per-share earnings growth for JNJ.

Growth Metrics

Financial Strength

Both Johnson & Johnson (JNJ) at 1.02 and Dr. Reddy's Laboratories (RDY) at 1.93 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Johnson & Johnson (JNJ) at 0.55 and Dr. Reddy's Laboratories (RDY) at 0.19 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Both Johnson & Johnson (JNJ) at 1.94% and Dr. Reddy's Laboratories (RDY) at 55.06% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Johnson & Johnson (JNJ) at 80.12% and Dr. Reddy's Laboratories (RDY) at 22.72% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Both Johnson & Johnson (JNJ) at 41.92 and Dr. Reddy's Laboratories (RDY) at 41.42 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Dr. Reddy's Laboratories (RDY) at 0.04 sits in the cheaper P/S ratio quartile while Johnson & Johnson (JNJ) at 6.69 prices around its industry’s middle — RDY costs less per dollar of sales, though read it alongside growth and margins.

Both look rich against book: Johnson & Johnson (JNJ) at 8.16 sits in the upper P/B ratio quartile, and Dr. Reddy's Laboratories (RDY) at 18.16 prices even higher, above its industry range.

Valuation Metrics